© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Staurosporine came to light in the 1970s after extraction from a species of Streptomyces. Natural products, especially those produced by soil-dwelling bacteria, have a track record in drug discovery. Many older scientists remember poring over obscure samples, hoping for the next penicillin. Staurosporine’s discovery drew attention not just because it came from an exotic bacteria, but also due to the remarkable biological effects researchers noticed almost immediately. Back then, tools for screening and purification looked primitive by today’s standards—hand-driven chromatography columns, detection by eye, basic spectrometry. Even with these limitations, the impact of staurosporine on protein kinases leapt off the lab bench. Since then, the path of research has evolved, driven by a steady push for deeper insight into how this molecule interacts with cells.
Across laboratories worldwide, staurosporine enjoys near-legendary status among kinase inhibitors. In its pure form, it usually appears as fine white or off-white powder. As a broad-spectrum kinase inhibitor, it gained a following in cell signaling studies and apoptosis induction. Its ability to trigger cell death almost anywhere it’s applied means researchers often rely on it during assays that test the robustness of new cell lines or treatments. Easy to dilute in common solvents like DMSO, staurosporine makes its way into a wide range of protocols focused on deciphering the tangled web of cellular communication.
Staurosporine carries the chemical formula C28H26N4O3 with a molecular weight around 466.54 g/mol. Its structure—marked by two indole rings fused at a central core—screams complexity and elegance to any synthetic chemist who spends years trying to make such molecules. Solubility in organic solvents remains high, but it barely dissolves in water. Those who’ve handled the powder know it clings to the walls of vials, necessitating careful weighing and mixing. The compound decomposes under prolonged exposure to light or heat, so most labs store it at minus-twenty freezers and in amber vials. Purity standards for reliable research usually hover above 98%, but even tiny impurities can skew results, demanding further scrutiny with HPLC and NMR.
Proper labeling of staurosporine stocks matters more than most admit. Even a small volume of unknown or degraded material can ruin weeks of cell culture work. Standard bottles come marked with batch number, expiry date, recommended storage temperature, and a lot-specific certificate of analysis. Reliable suppliers include detailed spectra and purity data, allowing researchers to double check identity and cleanliness before adding it to delicate experiments. Concentrations in stock solutions hover around 1–10 mM depending on lab protocol, always prepared in DMSO. Tracking every aliquot and freezing cycle minimizes variability and maximizes reproducibility—lessons hammered home by senior researchers over years of repeat experiments.
Industrial quantities of staurosporine require fermentation of Streptomyces, often Streptomyces staurosporeus. Growing the bacteria on specific media triggers the biosynthesis pathway, followed by extraction with organic solvents like chloroform or ethyl acetate. The crude mixture undergoes purification steps—usually flash chromatography, then high-pressure liquid chromatography. Intermediate fractions see scrutiny by UV absorption and mass spectrometry to nail down the right peak. Even with advances in synthetic chemistry, the natural extraction process tends to deliver large amounts more efficiently than any route built piece by piece. Costs climb sharply with the need for ultra-pure material, pushing chemical suppliers to develop ever-better purification techniques.
Tinkering with the staurosporine skeleton has yielded a family of analogs, many aimed at boosting selectivity or reducing toxicity. Chemists swap out functional groups in hopes of changing how the molecule fits against specific kinases. Adding or removing methyl groups, replacing an oxygen here or a nitrogen there, exploring every nook of reactivity—the work continues, because every new analog can open a door in targeted therapy or research tools. Synthetic branches like UCN-01 and midostaurin stem directly from these early modification attempts, each with uses in the clinic or research pipeline.
Staurosporine also goes by NSC 288387, AM-2282, or STS in countless papers. Drug developers have introduced derivatives under names like Midostaurin (PKC412) and UCN-01, each built off its foundational structure. Product catalogs offer it under the basic name, but the same science underlies a host of related research molecules that share the kinase-blocking core. The variety fills shelves with vials of similar but distinct compounds, which makes careful reading of product numbers and labels essential. A slip with synonyms has caused more than one mix-up as researchers order or interpret samples.
Anyone preparing or handling staurosporine knows to treat it with respect. It readily penetrates skin and eyes, both routes capable of harming researchers through even brief exposure. Research institutions require use of gloves, lab coats, and ventilated hoods. Staurosporine’s high toxicity further means every spill or mislabeled stock demands immediate attention. Stringent disposal protocols—solvent-neutralization, double-bagging waste, distinct labeling—reflect the dangers. Training junior lab members on these rules forms a key part of onboarding, and reminders hang on bulletin boards. One overlooked vial can threaten not just experiments, but the health of everyone in the lab.
Broad inhibition of protein kinases made staurosporine a staple in early studies of signal transduction and programmed cell death. Apoptosis researchers count on it to consistently clear cells from culture—making way for robust positive controls in caspase and cytochrome c assays. Neuroscientists, oncologists, immunologists, and even plant biologists have reached for staurosporine at some point. The compound’s ability to reveal vulnerabilities in cancer cell lines or trigger robust responses in neurons under study have kept it in use for decades. Staurosporine often shows up as the “gold standard” comparison when new kinase inhibitors enter the scene.
In the world of kinase biochemistry, staurosporine appears in thousands of publications each year. Its value stretches far beyond an easy positive control. During my own doctoral work, staurosporine served as a stressor in apoptosis screens, flagging compounds that blunted or mimicked its effects. The research community appreciates not only the reliability of the effect, but also the insight it provides into the web of proteins that regulate growth, death, and differentiation. Commercial drug developers found inspiration in its structure—a springboard to new, more selective inhibitors. As techniques like CRISPR and high-throughput screening shift the research landscape, staurosporine remains a fixture in illustration, benchmarking mixes and methods.
Every step forward with staurosporine involved close attention to its dark side—toxicity. In animal models, and in cell systems from yeast to primates, staurosporine wreaks havoc when unrestrained. The very activity that makes it a powerful cell biology tool also limits its direct clinical application. Acute exposure induces cell rounding, membrane blebbing, and DNA fragmentation—the markers of catastrophic cell death. For pharmaceutical testing, researchers mapped dose ranges meticulously to avoid off-target toxicity, using it now as a cautionary tale for kinase inhibitor drug design. Experience in the lab emphasizes strict dose-response assessment and redundancy in safety checks.
The pipeline for kinase inhibitors keeps growing, and the days of using broad shotgun inhibitors like staurosporine in patients have long passed. The spirit of discovery lives on, though, as scientists continue using staurosporine to probe new targets and design better drugs. Next-generation analogs expand on its blueprint, adding fine-tuned selectivity and better tolerability. Single-cell omics, high-throughput drug screening, and advanced chemistry point toward a future where researchers dissect cell death in exquisite detail, armed with an arsenal of tools that all trace a legacy back to the first samples extracted from an unremarkable soil microbe. Attention to safety, detail, and innovation keeps staurosporine at the center of experimental design, anchoring old wisdom and new opportunity.
Most conversations about life-saving advances dodge around molecules tucked away in lab freezers. Staurosporine, though, pops up again and again in scientific papers, sometimes quietly, sometimes at center stage. For more than three decades, its name has lingered on every biologist’s tongue, especially those digging into the tangled world of cell signaling and cancer. I remember the first time I saw its effects under a microscope—cells trembling, then dying with tidy precision. For a scientist investigating why cancer cells refuse to die, that moment is unforgettable.
Cancer research depends on finding the right switches to push or pull. Staurosporine isn’t a drug in the traditional sense—nobody prescribes it at the doctor’s office—but it offers researchers a reliable way to poke the cell’s inner machinery. It inhibits a family of enzymes called protein kinases. These kinases control almost every aspect of a cell’s life: division, growth, even self-destruct mode. Scientists discovered that by dropping a dose of staurosporine on a dish of cancer cells, the cells start a process called apoptosis, or programmed cell death. Learning how this works helps explain why some cancer therapies succeed and others fizzle out.
Staurosporine has made a name for itself in studies related to brain health. Researchers often use staurosporine to mimic the cell death seen in neurodegenerative diseases like Alzheimer’s and Parkinson’s. By observing how neurons respond to its presence, scientists find new ideas for preventing cell loss in the brain. I've met graduate students who use staurosporine to test if new compounds might protect nerve cells from damage. It’s a testbed, a model that lets teams around the world compare discoveries, sometimes unlocking fresh hope for devastating conditions.
Pharmaceutical companies keep a close watch on anything that can expose cancer cell weaknesses. Staurosporine routinely leads screening tests in the search for new cancer drugs. Because it blocks so many types of kinases, it helps reveal which pathways control the cell’s life-or-death choices. If a cancer cell survives staurosporine, it usually means something special about its biology. Researchers then try to figure out what gives these survivor cells their edge, then look for ways to target that process specifically.
Staurosporine comes with risks that demand respect. It’s highly toxic to all kinds of cells, not just the ones researchers want to target. Labs use stringent safety measures—gloves, hoods, disposable pipettes—mostly to avoid accidental contact or breathing in its dust. Not meant for direct use in living people, staurosporine’s value stays in the research lab, supporting breakthroughs before ideas become safe treatments.
People worry about cancer, Alzheimer's, and heart disease, and rightly so. By using molecules like staurosporine, researchers uncover details nobody could guess by just peering through a microscope or reading a genetics textbook. The search for better medicines depends on deep respect for tools that can silence, activate, or transform cells in moments. For all the drama packed into its tiny structure, staurosporine keeps researchers honest. It forces us to look closer at the molecules we design for tomorrow’s medicine—no shortcuts, no easy guesses, just real results that have to hold up in the clinic, not just the lab.
Years spent reading research articles can make a person cynical about the hype each new laboratory compound gets. Not many chemicals manage to keep their buzz. Staurosporine, though, continues to stand out. Originally pulled from a bacterium called Streptomyces staurosporeus, researchers didn’t take long to realize this molecule could stall numerous enzymes often central to cell processes. Its punch doesn’t come from fancy structure; the real story sits in what it does to kinases.
Kinases rank among the cell’s master controllers. They move phosphate groups onto proteins, which turns all sorts of switches inside a cell. Staurosporine slips in and gums up this process. It acts as a small-molecule inhibitor, especially against protein kinases—enzymes that play roles in cell growth, differentiation, and survival. The molecule does so by stuffing itself into the ATP-binding pocket of these kinases, making sure ATP itself can’t attach and fuel more enzyme action. Without that transfer, the enzyme loses its power to do anything.
This ATP-pocket jamming isn’t elegant if you crave selectivity. Staurosporine casts a wide net and captures many kinases at once. The molecule’s lack of pickiness landed it as a hammer for basic discovery early on but stopped it short from drug development. Broad activity offers excellent lessons about the importance of phosphorylation in almost every process—apoptosis, cancer progression, neuronal activity—but knocks over too many dominoes at once for safe therapy.
Expose cells to staurosporine, and the downstream consequences come quickly. Most obviously, it sparks apoptosis, or programmed cell death. This comes as kinases that hush death signals freeze up; others tied to cell cycle get blocked, too. That’s why staurosporine helped scientists map out pathways involved in cell death and clearance. The effect depends on cell type and dose. For example, in neuron cultures, even small amounts can start the machinery for apoptosis, which lines up with what’s seen during neurodegenerative states. In cancer cell lines, it can force cells to die that ignore other signals. This punch makes it a mainstay in experiments exploring cell death or survival.
Staurosporine’s story points to a common trap in drug discovery—what works for basic research rarely works for patients. The molecule’s catch-all approach exposes every kinase, even those needed for normal tissue maintenance. Studying it led to the creation of more selective inhibitors, now popular in cancer treatment and immunology. Pharmaceutical companies learned to design compounds based on the structure of staurosporine but tweaked their chemistry to home in on specific kinases. Drugs like imatinib or sunitinib exist because chemists saw both the promise and pitfalls of staurosporine’s approach.
No one grabs staurosporine for the clinic, but it remains a staple for bench scientists. It teaches that sometimes, a blunt instrument uncovers hidden logic inside the cell. Careful design, targeted inhibition, and relentless follow-up can turn that knowledge into therapy. As understanding widens, staurosporine still reminds us the tools of good science never truly go out of style, even if they never reach the pharmacy shelf.
Staurosporine serves as one of those small-molecule tools that ambitious researchers rely on when probing cell signaling. Its ability to block protein kinases puts it at the center of countless cancer, neuroscience, and cell death studies. The catch? Throw it on the shelf with the rest of your chemicals, and you risk wasting both your time and hard-earned grant money.
Many labs overlook basic storage rules and end up with degraded products. Staurosporine spoils quickly under the wrong conditions. From personal experience, I’ve seen labs return to half-empty vials caked with yellow residue, only to realize light and temperature shifts have rendered their experiments unreliable. Staurosporine doesn’t do well with too much air, moisture, or light. Think of it like milk – leave it out at room temperature or in sunlight and you’re pouring money down the drain.
Best practice involves putting staurosporine stock straight into a -20°C freezer. Most suppliers send it as a lyophilized powder, so sticking the container straight in a sealed bag helps block out humidity and oxygen. Once you dissolve it (often in DMSO), the clock really starts ticking. Light degrades solutions quickly, so using foil-wrapped vials helps. In my old workplace, fluorescent lights turned a fresh aliquot murky within a week. Most protocols say to use fresh solutions – toss what’s left after two weeks or risk failed experiments.
Several publications have documented staurosporine’s rapid degradation at room temperature and exposure to moisture. Data from storage studies show loss of activity even after a few days when kept on a bench top. Many distributors recommend keeping vials tightly capped, stored below -20°C, and protected from light at all times. A dissolved solution in DMSO should remain in amber or foil-wrapped vials in the freezer, away from freeze-thaw cycles. Not following these conditions leads to uncertain concentrations and less reproducible data.
It’s rare to pull staurosporine out, use the whole vial, and never return for more. Folks often aliquot stocks: thaw once, split into small volumes, refreeze quickly. This helps dodge repeated freeze-thaw damage. Labeling each tube by date, keeping everything organized, and recording each thaw round stops confusion when experiments go sideways.
Labs swapping staurosporine between teams or projects need transparency. Clear labeling, shared handling protocols, and immediate communication about expiry concerns avoid surprises later. Contamination occurs easily if staff use “dirty” pipette tips or handle tubes with gloved hands touched by moisture. This sets off a contamination chain reaction, making fresh research much harder than it has to be.
Training staff matters more than any equipment purchase. Ensure each new lab partner learns proper staurosporine storage, solution prep, and tracking. Digital inventory with reminder alarms for expiration can help take pressure off memory.
Vendors play a role as well. Some manufacturers now include light-blocking vials and humidity monitors, reducing the chance of spoilage during transit. More detailed documentation would push most labs to develop better routines.
Treating this chemical with the seriousness it deserves means better results, fewer wasted materials, and tighter experiments – something every research budget can appreciate.
Staurosporine packs a punch as a kinase inhibitor, shutting down a wide range of protein kinases that play big roles in cell signaling. Investigators reach for this compound when they want a fast and reliable way to trigger cell death or to probe the machinery of apoptosis. The breadth of its action means careful handling makes or breaks any experiment. As someone who’s spent long hours at the bench, I learned firsthand that better planning—especially for reagents like staurosporine—can mean the difference between a clear result and a confusing mess.
Researchers find a fairly broad range in reported staurosporine concentrations. Most publications point to a sweet spot between 0.01 and 1 micromolar (μM) for cell culture work. For most mammalian cells, 0.1 μM gives a pronounced effect, such as rapid activation of cell death signals, without instantly wiping out the culture. Pushing up to 1 μM almost always leads to fast, dramatic apoptosis, and lower end doses—closer to 0.01 μM—set off subtler shifts in cell state.
Back in grad school, our lab settled on 0.5 μM as a go-to starting point for most experiments with human cancer cells. This matched up with published studies in Cell Death & Disease and Biochemical Journal. Importantly, dose-response is never a set-it-and-forget-it situation. Toxicity can swing with cell type, confluency, and even age of the staurosporine stock. The tradeoff is a familiar one: too little, effects blur out; too much, the system breaks.
Staurosporine loses activity when left in DMSO at room temperature or through repeated freeze-thaw cycles. Researchers learned to make small aliquots and keep them at -20°C away from light to avoid surprises mid-experiment. I made the mistake once of skipping a fresh dilution—my cells took far longer to respond, and I wasted a whole batch. After that, I always checked for a quick effect with a known positive control before moving to full-scale tests.
Transparent reporting supports progress in science. Too often, protocols gloss over crucial factors: stock preparation, cell density at treatment, and timing of exposure. Top tier journals like Nature Methods push for detailed method sections to ensure others can reproduce findings. Dose matters, but other factors shift the window of effect. Using identical concentrations between labs without aligning on conditions can lead researchers astray.
Staurosporine is toxic. Gloves, bench protectors, and dedicated pipettes help limit exposure. Exhaust fans keep fumes away. Even when running under time pressure, it pays to treat each transfer or dilution with patience.
For routine studies, starting at 0.1 μM or 0.5 μM—then running a titration across cell types—lays out clear, interpretable results. Measuring at different time points gives a sense of both onset and duration. Controls with DMSO, plus viability stains like MTT or trypan blue, ensure what’s seen is real. Drawing from my own hits and misses, there isn’t a simple “one size fits all,” but good record-keeping, clear rationale, and patience keep experiments on track and results trustworthy.
Scientists get excited about staurosporine because of its major impact on cell signaling research. It blocks protein kinases, so it finds its way into cancer, neurobiology, and apoptosis experiments all over the world. Before any experiment gets off the ground, researchers need to dissolve staurosporine. This step can decide whether a study hits a roadblock or gets rolling.
Staurosporine looks like a straightforward powder, but adding it straight to water leads nowhere. Water simply does not break it down. This can catch some folks off guard if they expect easy mixing like common lab salts. I learned fast during my early days in graduate school: drop staurosporine in phosphate-buffered saline, watch nothing happen, and realize time and expensive reagents just got wasted.
The stuff just clumps and floats, refusing to dissolve. Any scientist who tries to force the issue winds up frustrated, fighting cloudiness in their samples and questioning their protocol. Data from Sigma-Aldrich and MedChemExpress back up that hands-on reality: water leaves staurosporine undissolved.
Dimethyl sulfoxide, better known as DMSO, ends up being the hero for tough-to-dissolve molecules like staurosporine. Add even a small amount of DMSO, and the powder clears within seconds. Most protocols call for 1 to 10 millimolar stock solutions in DMSO. In my own projects, I always saw DMSO transform stubborn pellets into a clear solution.
The reason rests in chemistry. Staurosporine has a complex multi-ring structure. This gives it low polarity, which does not mix well with water’s hydrogen bonding. DMSO, on the other hand, welcomes complex organic molecules because of its own polar and nonpolar qualities. Researchers trust DMSO for dissolving alkaloids, small molecule inhibitors, and other finicky compounds.
No lab decision comes free of drawbacks. DMSO has a way of acting on living things all by itself. Add too much DMSO to cell cultures, and the cells end up stressed or dead. For that reason, researchers keep the final DMSO concentration below 0.1% whenever possible. Lab guidelines stress running “vehicle controls,” so any effect comes from the experimental compound, not the solvent.
Contamination also sneaks in if someone reuses DMSO stocks or miscalculates concentrations. Once, a friend tracked down odd cell death rates to an old DMSO bottle sitting on a warm shelf.
Navigating solubility means more than following a recipe. Poor solubility can bury results under false negatives and wasted runs. Good practices—testing small batches, logging DMSO volumes, and controlling for solvent effects—keep both experiments and reputations intact.
Staurosporine’s story highlights the importance of reading protocols, learning from peers, and checking the literature. Reliable research comes from details as simple as dissolving reagents the right way. That's the heart of strong experimental science.
| Names | |
| Preferred IUPAC name | (2S,3R,4R,6R)-4-(dimethylamino)-3-hydroxy-6-methoxy-3,4,5,6-tetrahydro-1H,12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-2-carboxamide |
| Other names |
AM-2282 Streptococcin |
| Pronunciation | /staʊˈrɒspəˌriːn/ |
| Identifiers | |
| CAS Number | 62996-74-1 |
| Beilstein Reference | 3622325 |
| ChEBI | CHEBI:65310 |
| ChEMBL | CHEMBL254 |
| ChemSpider | 21508302 |
| DrugBank | DB02010 |
| ECHA InfoCard | 100.021.178 |
| EC Number | 2.7.11.1 |
| Gmelin Reference | 607211 |
| KEGG | C06102 |
| MeSH | D016246 |
| PubChem CID | 44259 |
| RTECS number | GM6000000 |
| UNII | UW47V4X7U5 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C28H26N4O3 |
| Molar mass | 466.535 g/mol |
| Appearance | Yellow powder |
| Odor | Odorless |
| Density | 0.00121 g/cm³ |
| Solubility in water | Insoluble |
| log P | 3.3 |
| Acidity (pKa) | 13.4 |
| Basicity (pKb) | 12.52 |
| Dipole moment | 5.5 ± 1.1 D |
| Thermochemistry | |
| Std enthalpy of combustion (ΔcH⦵298) | -6524 kJ/mol |
| Pharmacology | |
| ATC code | L01XX39 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes serious eye irritation, may cause respiratory irritation. |
| GHS labelling | GHS02, GHS06, GHS08 |
| Pictograms | GHS06, GHS08 |
| Signal word | Danger |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | H315-H319-H335 |
| NFPA 704 (fire diamond) | Health: 3, Flammability: 2, Instability: 0, Special: - |
| Flash point | > 230 °F |
| Lethal dose or concentration | LD₅₀ (mouse, intraperitoneal): 2 mg/kg |
| LD50 (median dose) | 1.39 mg/kg (Mouse, intravenous) |
| NIOSH | Not Listed |
| REL (Recommended) | 1 μM |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
K252a UCN-01 Bisindolylmaleimide I Midostaurin Go6976 |
